Inhibrx Biosciences (INBX) Receivables (2023 - 2025)
Historic Receivables for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $837000.0.
- Inhibrx Biosciences' Receivables rose 2455.36% to $837000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $837000.0, marking a year-over-year increase of 2455.36%. This contributed to the annual value of $438000.0 for FY2024, which is 6837.55% down from last year.
- According to the latest figures from Q3 2025, Inhibrx Biosciences' Receivables is $837000.0, which was up 2455.36% from $967000.0 recorded in Q2 2025.
- Inhibrx Biosciences' Receivables' 5-year high stood at $1.4 million during Q4 2023, with a 5-year trough of $214000.0 in Q1 2025.
- Over the past 3 years, Inhibrx Biosciences' median Receivables value was $837000.0 (recorded in 2025), while the average stood at $813571.4.
- Its Receivables has fluctuated over the past 5 years, first tumbled by 7133.57% in 2024, then surged by 2455.36% in 2025.
- Over the past 3 years, Inhibrx Biosciences' Receivables (Quarter) stood at $1.4 million in 2023, then crashed by 71.34% to $397000.0 in 2024, then skyrocketed by 110.83% to $837000.0 in 2025.
- Its Receivables stands at $837000.0 for Q3 2025, versus $967000.0 for Q2 2025 and $214000.0 for Q1 2025.